伏诺拉生与雷贝拉唑治疗反流性食管炎的临床疗效比较

Clinical efficacy of vonoprazan versus rabeprazole for treatment of reflux esophagitis:a comparative study

目的比较伏诺拉生和雷贝拉唑治疗反流性食管炎(RE)的临床疗效。方法将60例RE患者随机分为观察组和对照组,每组30例。观察组给予伏诺拉生治疗,对照组给予雷贝拉唑治疗,疗程均为14 d。比较两组患者烧心症状累积完全缓解率,以及治疗前后胃食管反流病症状频率量表(FSSG)评分、匹兹堡睡眠质量指数(PSQI)评分,记录治疗过程中不良反应的发生情况。结果治疗后的第1~7天,观察组全天和夜间烧心症状累积完全缓解率均高于对照组(均P<0.05),两组患者日间烧心症状累积完全缓解率差异无统计学意义(P>0.05);治疗14 d后,两组患者的FSSG评分、PSQI评分均较治疗前降低,且观察组低于对照组(均P<0.05);治疗过程中两组患者均无明显不良反应发生。结论与雷贝拉唑相比,伏诺拉生可以更好地改善RE患者烧心症状与睡眠质量,且安全性良好。

Objective To compare the clinical efficacy of vonoprazan versus rabeprazole for the treatment of reflux esophagitis(RE).Methods Sixty patients with RE were randomly divided into observation group(n=30)and control group(n=30).The observation group was treated with vonoprazan,and the control group was treated with rabeprazole.The treatment lasted for 14 days in both groups.The two groups were compared in terms of the cumulative complete remission rate of heartburn symptom,as well as the pre-and post-treatment scores of the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease(FSSG)and the Pittsburgh Sleep Quality Index(PSQI)scores.The incidence of treatment-emergent adverse reactions was recorded.Results From day 1 to day 7 after the treatment,the observation group exhibited higher cumulative complete remission rates of heartburn symptom for a whole day and at night than the control group(all P<0.05),and there was no statistically significant difference in the cumulative complete remission rate of daytime heartburn symptom between the two groups(P>0.05).Fourteen days after the treatment,FSSG scores and PSQI scores were decreased in both groups as compared with the pre-treatment scores,and the observation group yielded lower scores than the control group(all P<0.05).No evident adverse reactions occurred in the two groups during the treatment.Conclusion Compared with rabeprazole,vonoprazan can preferably improve heartburn symptom and sleep quality in patients with RE,exhibiting favorable safety.